US equities
|
MU
$1,042.67
▼-2.11%
NVDA
$229.16
▲+0.34%
SNDK
$1,720.08
▼-1.14%
TSLA
$357.83
▲+0.85%
INTC
$118.75
▼-1.23%
AMD
$607.89
▼-0.63%
GOOGL
$340.62
▼-1.01%
LITE
$1,063.24
▲+9.47%
MU
$1,042.67
▼-2.11%
NVDA
$229.16
▲+0.34%
SNDK
$1,720.08
▼-1.14%
TSLA
$357.83
▲+0.85%
INTC
$118.75
▼-1.23%
AMD
$607.89
▼-0.63%
GOOGL
$340.62
▼-1.01%
LITE
$1,063.24
▲+9.47%
FinancialContent
Watchlist
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
My watchlist
My portfolio
Recent quotes
Regeneron Pharmaceuticals
(NQ:
REGN
)
737.75
-20.52 (-2.71%)
Delayed Quote
Updated: 11:13 AM EDT, Oct 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
↗
Today 11:02 EDT
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases,...
Via
MarketBeat
Topics
ETFs
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment
September 30, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...
Via
StockStory
Topics
Artificial Intelligence
Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?
↗
September 28, 2026
The healthcare company will release its third-quarter results next month.
Via
The Motley Fool
1 Profitable Stock with Impressive Fundamentals and 2 That Underwhelm
September 28, 2026
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Via
StockStory
Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount
↗
September 09, 2026
Via
Chartmill
Regeneron Pharmaceuticals (NASDAQ:REGN) Surges After Crushing Q2 Estimates with Revenue and EPS Beat
↗
July 30, 2026
Via
Chartmill
Regeneron Pharmaceuticals (NASDAQ:REGN): A Quality Value Stock with Decent Growth and a Clear Discount
↗
July 24, 2026
Via
Chartmill
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts
↗
September 23, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development...
Via
MarketBeat
Topics
ETFs
Is Regeneron Stock a Bargain Below $800?
↗
September 22, 2026
The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.
Via
The Motley Fool
Topics
Intellectual Property
1 S&P 500 Stock Worth Your Attention and 2 We Ignore
September 22, 2026
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Via
StockStory
Topics
Stocks
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
↗
September 15, 2026
Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.
Via
The Motley Fool
Topics
Regulatory Compliance
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum
↗
September 14, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global...
Via
MarketBeat
Topics
Intellectual Property
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth
↗
September 12, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo...
Via
MarketBeat
Topics
ETFs
3 Reasons to Avoid REGN and 1 Stock to Buy Instead
September 08, 2026
Although Regeneron (currently trading at $845.04 per share) has gained 8.1% over the last six months, it has trailed the S&P 500’s 13.6% return during that p...
Via
StockStory
Topics
Stocks
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
↗
September 04, 2026
They could both outperform the market over the medium term, but one appears to have a clear edge.
Via
The Motley Fool
Topics
Intellectual Property
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
↗
September 02, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 4.59% on an annualized basis producing an average annual return of 17.79%. Currently, Regeneron...
Via
Benzinga
$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
↗
August 24, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 6.17% on an annualized basis producing an average annual return of 19.2%. Currently, Regeneron...
Via
Benzinga
Q2 Rundown: Natera (NASDAQ:NTRA) Vs Other Biotechnology Stocks
August 17, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...
Via
StockStory
Topics
Artificial Intelligence
2 GLP-1 Stocks That Could Double Your Money by 2031
↗
August 16, 2026
They are fairly risky, but their potential upside is massive.
Via
The Motley Fool
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)
↗
August 14, 2026
They are way more than just GLP-1 stocks.
Via
The Motley Fool
Topics
Intellectual Property
If You Invested $1000 In Regeneron Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today
↗
August 14, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.69% on an annualized basis producing an average annual return of 22.03%. Currently, Regeneron...
Via
Benzinga
The Top 5 Analyst Questions From Regeneron’s Q2 Earnings Call
August 06, 2026
Regeneron’s second quarter was marked by strong commercial execution and robust product demand, resulting in financial results that surpassed Wall Street’s e...
Via
StockStory
Topics
Earnings
1 Value Stock with Promising Prospects and 2 We Avoid
August 04, 2026
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...
Via
StockStory
Regeneron (REGN) Q2 2026 Earnings Call Transcript
↗
August 03, 2026
Revenue surged 17% as Dupixent and EYLEA HD posted record sales.
Via
The Motley Fool
Topics
Earnings
REGN Q2 Deep Dive: Pipeline Progress and Product Momentum Drive Outperformance
July 31, 2026
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 16.7% year on year to $4.29 billion....
Via
StockStory
Regeneron (REGN) Q2 2026 Earnings Call Transcript
↗
July 30, 2026
Revenue surged 17% as Dupixent and EYLEA HD posted record sales.
Via
The Motley Fool
Topics
Earnings
Regeneron Pharmaceuticals Q2 Earnings Call Highlights
↗
July 30, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) reported second-quarter revenue growth of 17% from a year earlier to $4.3 billion, supported by continued strength in Dupixent, EYLEA HD and Libtayo. Non-GAAP...
Via
MarketBeat
Topics
ETFs
Earnings
Regeneron’s (NASDAQ:REGN) Q2 CY2026: Strong Sales
July 30, 2026
Biotech company Regeneron (NASDAQ:REGN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 16.7% year on year to $4.29 billi...
Via
StockStory
Topics
Artificial Intelligence
Regeneron (REGN) To Report Earnings Tomorrow: Here Is What To Expect
July 28, 2026
Biotech company Regeneron (NASDAQ:REGN) will be reporting results this Thursday before the bell. Here’s what you need to know. Regeneron beat analysts’ reven...
Via
StockStory
Topics
Artificial Intelligence
3 Cash-Heavy Stocks with Questionable Fundamentals
July 27, 2026
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
